Sascha Berger, private biopharmaceutical investor; Shannon Eaker, CTO of Xcellbio; Edwin Stone, CEO of Cellular Origins; and ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.

Answering a random call was the serendipitous connection that led to Purdue Extension's new Downing Endowment for Community ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...